FDA Hands Out Speedy Voucher for Kids' Rare Disease Breakthrough
Published Date: 3/13/2025
Notice
Summary
The FDA just gave SpringWorks Therapeutics a special priority review voucher for their rare pediatric disease drug, Gomekli (mirdametinib), approved on February 11, 2025. This voucher speeds up the review of future drug applications, helping get important medicines to kids faster. Companies can use or sell these vouchers, which can save time and money in drug approval processes.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Company awarded tradable priority voucher
The FDA issued a priority review voucher to SpringWorks Therapeutics for GOMEKLI (mirdametinib) after the drug's approval on February 11, 2025. The voucher can be used or sold to speed the review of a future drug application, giving the company a tradable asset that can save time and money in the approval process.
Faster access to pediatric drugs
Priority review vouchers let companies speed the review of future drug applications, which can help get important medicines to children with rare diseases faster. Because companies can use or sell the voucher, this may lower time and money barriers to bringing pediatric treatments to market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in